The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | E-selectin antagonist uproleselan for R/R AML: efficacy and safety data
Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy and safety results for the E-selectin antagonist uproleselan, in addition to chemotherapy, for relapsed/refractory acute myeloid leukemia (NCT03616470). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
